T
Troy H. Guthrie
Researcher at Indiana University
Publications - 13
Citations - 4384
Troy H. Guthrie is an academic researcher from Indiana University. The author has contributed to research in topics: Vemurafenib & Ipilimumab. The author has an hindex of 9, co-authored 13 publications receiving 3819 citations.
Papers
More filters
Journal ArticleDOI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka,Howard L. Kaufman,Frances A. Collichio,Thomas Amatruda,Neil Senzer,Jason Chesney,Keith A. Delman,Lynn E. Spitler,Igor Puzanov,Sanjiv S. Agarwala,Mohammed M. Milhem,Lee D. Cranmer,Brendan D. Curti,Karl D. Lewis,Merrick I. Ross,Troy H. Guthrie,Gerald P. Linette,Gregory A. Daniels,Kevin J. Harrington,Mark R. Middleton,Wilson H. Miller,Jonathan S. Zager,Yining Ye,Bin Yao,Ai Li,Susan Doleman,Ari M. Vanderwalde,Jennifer Gansert,Robert Coffin +28 more
TL;DR: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma.
Journal ArticleDOI
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok,Bart Neyns,Gerald P. Linette,Sylvie Negrier,Jose Lutzky,Luc Thomas,William Waterfield,Dirk Schadendorf,Michael Smylie,Troy H. Guthrie,Jean-Jacques Grob,Jason Chesney,Kevin M. Chin,Kun Chen,Axel Hoos,Steven J. O'Day,Céleste Lebbé +16 more
TL;DR: Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg.
Journal ArticleDOI
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
Gerald Batist,Gopal Ramakrishnan,Chandra Sekhar Rao,Aruna Chandrasekharan,John Gutheil,Troy H. Guthrie,Pankaj Shah,Ali Khojasteh,Madhavan Krishnan Nair,Karen Hoelzer,Katherine Tkaczuk,Youn C. Park,Lily W. Lee +12 more
TL;DR: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Journal ArticleDOI
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
Nasser H. Hanna,Paul A. Bunn,Corey Langer,Lawrence H. Einhorn,Troy H. Guthrie,Thaddeus Beck,Rafat Ansari,Peter M. Ellis,Michael Byrne,Mark E. Morrison,Subramanian Hariharan,Benjamin Wang,Alan B. Sandler +12 more
TL;DR: Treatment with this dose and schedule of IP did not result in improved survival when compared with EP, and fewer patients receiving IP had grade 3/4 anemia, thrombocytopenia, neutropenIA, and febrile neutropania compared with patients receiving EP, but more had grade 2/4 diarrhea and vomiting.
Journal ArticleDOI
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Christine E. Swenson,Lois E. Bolcsak,Gerald Batist,Troy H. Guthrie,Katherine Tkaczuk,Harold Boxenbaum,Lauri Welles,Shein-Chung Chow,Rupinder Bhamra,Philip Chaikin +9 more
TL;DR: There was a correlation between the plasma AUC0−∞ of total doxorubicin and the degree of myelosuppression in patients receiving conventional doxorbicin, but this correlation was not found in patients received TLC D-99.